RxSight Statistics
Total Valuation
RxSight has a market cap or net worth of $505.12 million. The enterprise value is $287.82 million.
Important Dates
The next estimated earnings date is Monday, August 4, 2025, after market close.
| Earnings Date | Aug 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RxSight has 40.64 million shares outstanding. The number of shares has increased by 11.26% in one year.
| Current Share Class | 40.64M |
| Shares Outstanding | 40.64M |
| Shares Change (YoY) | +11.26% |
| Shares Change (QoQ) | +0.38% |
| Owned by Insiders (%) | 5.31% |
| Owned by Institutions (%) | 80.93% |
| Float | 32.20M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.33 |
| Forward PS | 2.87 |
| PB Ratio | 1.81 |
| P/TBV Ratio | 1.81 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.94 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.68, with a Debt / Equity ratio of 0.04.
| Current Ratio | 12.68 |
| Quick Ratio | 11.45 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,755.33 |
Financial Efficiency
Return on equity (ROE) is -11.98% and return on invested capital (ROIC) is -10.06%.
| Return on Equity (ROE) | -11.98% |
| Return on Assets (ROA) | -9.29% |
| Return on Invested Capital (ROIC) | -10.06% |
| Return on Capital Employed (ROCE) | -12.70% |
| Revenue Per Employee | $297,811 |
| Profits Per Employee | -$53,303 |
| Employee Count | 498 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 1.97 |
Taxes
In the past 12 months, RxSight has paid $59,000 in taxes.
| Income Tax | 59,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.17% in the last 52 weeks. The beta is 1.21, so RxSight's price volatility has been higher than the market average.
| Beta (5Y) | 1.21 |
| 52-Week Price Change | -78.17% |
| 50-Day Moving Average | 14.47 |
| 200-Day Moving Average | 30.83 |
| Relative Strength Index (RSI) | 32.93 |
| Average Volume (20 Days) | 670,899 |
Short Selling Information
The latest short interest is 4.96 million, so 12.21% of the outstanding shares have been sold short.
| Short Interest | 4.96M |
| Short Previous Month | 4.78M |
| Short % of Shares Out | 12.21% |
| Short % of Float | 15.41% |
| Short Ratio (days to cover) | 5.96 |
Income Statement
In the last 12 months, RxSight had revenue of $148.31 million and -$26.55 million in losses. Loss per share was -$0.67.
| Revenue | 148.31M |
| Gross Profit | 106.59M |
| Operating Income | -36.86M |
| Pretax Income | -36.75M |
| Net Income | -26.55M |
| EBITDA | -33.63M |
| EBIT | -36.86M |
| Loss Per Share | -$0.67 |
Full Income StatementBalance Sheet
The company has $229.34 million in cash and $12.04 million in debt, giving a net cash position of $217.30 million or $5.35 per share.
| Cash & Cash Equivalents | 229.34M |
| Total Debt | 12.04M |
| Net Cash | 217.30M |
| Net Cash Per Share | $5.35 |
| Equity (Book Value) | 279.32M |
| Book Value Per Share | 6.88 |
| Working Capital | 265.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.47 million and capital expenditures -$4.05 million, giving a free cash flow of -$20.52 million.
| Operating Cash Flow | -16.47M |
| Capital Expenditures | -4.05M |
| Free Cash Flow | -20.52M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
Gross margin is 71.87%, with operating and profit margins of -24.85% and -17.90%.
| Gross Margin | 71.87% |
| Operating Margin | -24.85% |
| Pretax Margin | -17.86% |
| Profit Margin | -17.90% |
| EBITDA Margin | -22.67% |
| EBIT Margin | -24.85% |
| FCF Margin | n/a |
Dividends & Yields
RxSight does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.26% |
| Shareholder Yield | -11.26% |
| Earnings Yield | -5.26% |
| FCF Yield | -4.06% |
Dividend DetailsAnalyst Forecast
The average price target for RxSight is $39.30, which is 216.17% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.30 |
| Price Target Difference | 216.17% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 14.66% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RxSight has an Altman Z-Score of 30.47 and a Piotroski F-Score of 4.
| Altman Z-Score | 30.47 |
| Piotroski F-Score | 4 |
